Warfarin response

Common Name(s)

Warfarin response

Warfarin is a widely prescribed anticoagulant for the prevention of thromboembolic diseases for subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement ({27:Yuan et al., 2005}). The dose requirement is highly variable, both interindividually and interethnically. Variation in the VKORC1 gene is believed to be the most important individual predictor of warfarin dose, accounting for about 30% of the variance observed in dosing ({17:Ross et al., 2010}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Warfarin response" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Warfarin response" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Warfarin response" returned 35 free, full-text research articles on human participants. First 3 results:

Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
 

Author(s): Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, Richard C Becker, G√ľnter Breithardt, Scott D Berkowitz, Jonathan L Halperin, Graeme J Hankey, Werner Hacke, Kenneth W Mahaffey, Christopher C Nessel, Daniel E Singer, Keith A A Fox, Manesh R Patel

Journal: Circulation. 2016 Jul;134(2):e7-8.

 

Last Updated: 12 Jul 2016

Go To URL
Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.
 

Author(s): Sameer Ather, Aditi Shendre, T Mark Beasley, Todd Brown, Charles E Hill, Sumanth D Prabhu, Nita A Limdi

Journal: Am. J. Cardiol.. 2016 Jul;118(2):232-6.

 

Candidates for chronic warfarin therapy often have co-morbid conditions, such as heart failure, with reduced left ventricular ejection fraction. Previous reports have demonstrated an increased risk of over-anticoagulation due to reduced warfarin dose requirement in patients with decompensated ...

Last Updated: 25 Jun 2016

Go To URL
Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)".
 

Author(s): Ioana R Preston, Kari E Roberts, Dave P Miller, Ginny P Sen, Mona Selej, Wade W Benton, Nicholas S Hill, Harrison W Farber

Journal: Circulation. 2016 May;133(20):e662.

 

Last Updated: 17 May 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Warfarin response" returned 2 free, full-text review articles on human participants. First 3 results:

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
 

Author(s): Andrea L Jorgensen, Richard J FitzGerald, James Oyee, Munir Pirmohamed, Paula R Williamson

Journal: PLoS ONE. 2012 ;7(8):e44064.

 

Warfarin is a highly effective anticoagulant however its effectiveness relies on maintaining INR in therapeutic range. Finding the correct dose is difficult due to large inter-individual variability. Two genes, CYP2C9 and VKORC1, have been associated with this variability, leading ...

Last Updated: 6 Sep 2012

Go To URL
The pharmacogenetics of the response to warfarin in Chinese.
 

Author(s): May P S Lam, Bernard M Y Cheung

Journal: Br J Clin Pharmacol. 2012 Mar;73(3):340-7.

 

Warfarin is a commonly used oral anticoagulant with a narrow therapeutic range and large interindividual variability in daily dose. Compared with Caucasians, Chinese are known to require lower doses of warfarin. Differences between Caucasians and Chinese in the allelic frequencies ...

Last Updated: 14 Feb 2012

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9
 

Status: Not yet recruiting

Condition Summary: Healthy Subjects

 

Last Updated: 5 Jul 2011

Go to URL